New therapeutic options for chronic wounds

Lı́mová, Markéta

doi:10.1016/s0733-8635(01)00030-4

Cited by 14 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its success in speeding the healing of acute wounds appears to be related to other factors than the persistence of donor DNA or basement membrane restoration. For the treatment of deep chronic wounds, the same manufacturer developed a monolayer product, with live human fibroblasts in a collagen matrix, without a keratinocyte layer [15], which is currently not available. A further developed version of Apligraf aiming to omit the use of xenogenic collagen and utilizing human collagen produced de novo by the human fibroblasts is in late-stage development (VCT01, company information).…”

Section: Cell-containing Devicesmentioning

confidence: 99%

Long‐Term Followup of Dermal Substitution with Acellular Dermal Implant in Burns and Postburn Scar Corrections

Juhász

Kiss

Lukács

et al. 2010

Dermatology Research and Practice

View full text Add to dashboard Cite

Full-thickness burn and other types of deep skin loss will result in scar formation. For at least partial replacement of the lost dermal layer, there are several options to use biotechnologically derived extracellular matrix components or tissue scaffolds of cadaver skin origin. In a survey, we have collected data on 18 pts who have previously received acellular dermal implant Alloderm. The age of these patients at the injury varied between 16 months and 84 years. The average area of the implants was 185 cm2. Among those, 15 implant sites of 14 patients were assessed at an average of 50 months after surgery. The scar function was assessed by using the modified Vancouver Scar Scale. We have found that the overall scar quality and function was significantly better over the implanted areas than over the surrounding skin. Also these areas received a better score for scar height and pliability. Our findings suggest that acellular dermal implants are especially useful tools in the treatment of full-thickness burns as well as postburn scar contractures.

show abstract

Section: Cell-containing Devicesmentioning

confidence: 99%

Long‐Term Followup of Dermal Substitution with Acellular Dermal Implant in Burns and Postburn Scar Corrections

Juhász

Kiss

Lukács

et al. 2010

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…22,23,25,[35][36][37][38] Recent research has shown that true chronic wounds are biochemically different from acute wounds differing in their expression of growth factors, matrix metalloproteases, and various proteins. 22,23,35,37,38 The most frequent chronic wounds are diabetic foot ulcers, ulcers due to peripheral arterial occlusive disease, and venous ulcers. 25,38 A definition is that a wound failing to heal after 4 weeks is chronic, 38 a definition adopted by the American Diabetes Association for patients with diabetes foot wounds.…”

Section: Acute Versus Chronic Woundsmentioning

confidence: 99%

“…67,68 This led to several growth factors being tested in the treatment of diabetic foot ulcers. 17,18,22,23,36,37 Of these, recombinant human PDGF and GCSF (granulocyte colony stimulating factor) are the most widely studied. 17,18,22,23,36,37,42,43 The former is locally applied for the treatment of uninfected neuropathic ulcers in patients without compromised circulation, whereas the latter is administered subcutaneously for the treatment of infected ulcers.…”

Section: Rationale For Use Of Growth Factors In Diabetic Foot Ulcersmentioning

confidence: 99%

“…17,18,22,23,36,37 Of these, recombinant human PDGF and GCSF (granulocyte colony stimulating factor) are the most widely studied. 17,18,22,23,36,37,42,43 The former is locally applied for the treatment of uninfected neuropathic ulcers in patients without compromised circulation, whereas the latter is administered subcutaneously for the treatment of infected ulcers. 17,18,42 At present, only topical application of recombinant human PDGF has been approved by U.S. Food and Drug Administration and European authorities for the treatment of diabetic neuropathic ulcers.…”

Section: Rationale For Use Of Growth Factors In Diabetic Foot Ulcersmentioning

confidence: 99%

See 1 more Smart Citation

Growth Factors in the Treatment of Diabetic Foot Ulcers: New Technologies, Any Promises?

Παπάνας¹,

Maltezos

2007

The International Journal of Lower Extremity Wounds

View full text Add to dashboard Cite

Foot ulcers remain a common problem, leading to increased morbidity in patients with diabetes. Despite the progress that has been achieved in revascularization techniques as well as in off-loading to relieve high-pressure areas, diabetic foot wounds remain a clinical challenge. Growth factors are a major technological advance that promised to change the face of wound healing. The most important of growth factors are recombinant human platelet-derived growth factor-BB and granulocyte colony-stimulating factor. The former has been approved by the FDA for the treatment of neuropathic ulcers when there is adequate blood supply. The latter is less demonstrably useful. Advances include methods of delivering growth factors.

show abstract

“…12 Treatments involving the use of wound matrices provide promising new options for affecting the wound healing process. 12 -16 One such medical product, OASIS Wound Matrix (Cook Biotech Inc, West Lafayette, IN [ Figure 1]), derived from porcine small intestinal submucosa (SIS), has been used clinically to aid in the healing of difficult-to-heal and chronic wounds.…”

Section: Introductionmentioning

confidence: 99%